Single Nucleotide Polymorphism (SNP) Genotyping Market
Report ID: SQMIG35J2548
Report ID: SQMIG35J2548
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2548 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
158
|Figures:
78
Global Single Nucleotide Polymorphism (SNP) Genotyping Market size was valued at USD 36.64 Billion in 2024 and is poised to grow from USD 44.74 Billion in 2025 to USD 221.00 Billion by 2033, growing at a CAGR of 22.1% during the forecast period (2026-2033).
Technologies capable of identifying single-base changes in DNA are driving the global single nucleotide polymorphism (SNP) genotyping market growth because this ability is fundamental to personalized healthcare, agricultural breeding, and forensic identification. This is important because it links genetic markers with disease susceptibility, drug response or inheritance of traits and so informs clinical decisions and crop improvement strategies. The market started with early PCR-based methods in the 1990s, moved to array platforms in the 2000s, and now includes next-generation sequencing and CRISPR-inspired assays. The sector is changing rapidly, as evidenced by the introduction of large-scale population studies via Illumina’s Infinium arrays and the recent availability of nanopore-based kits for rapid point-of-care genotyping.
The key growth factor for single nucleotide polymorphism (SNP) genotyping market trends is the increasing need for precision therapeutics. This creates a cyclical effect between the generation of genomic data and drug pipelines. Pharmaceutical companies are moving towards biomarker-guided trials and require high-throughput, cost-effective platforms that stratify patients by allele frequencies. This drives investment into automated liquid handling and multiplexed assay solutions. That has resulted in the creation of scalable panels by biotech companies such as Thermo Fisher and Roche that reduce per-sample costs to under $30, enabling large-cohort oncology and rare-disease studies. Fast screening of elite germplasm in agriculture for drought-resistance alleles reduces breeding cycles, driving uptake of portable SNP kits and enhancing market volume.
How is AI-driven Automation Influencing the SNP Genotyping Market?
AI-driven automation is transforming single nucleotide polymorphism (SNP) genotyping market share, simplifying assay design, data acquisition and interpretation. Now, machine‐learning‐based models predict the optimal primer sets, reducing both experimental cycles and human error. Integrated workflows link laboratory robots with cloud-based analysis to allow labs to scale throughput while controlling costs. Quality checks in real time alert operators to anomalies and speed up decision making in research and clinical settings. These capabilities speed up the translation of raw genotype data into useful information, making the technology more appealing for large-scale population studies and precision-medicine initiatives.
In June 2024, Illumina launched an AI-enabled automated genotyping platform that speeds sample processing and improves data reliability, furthering market efficiency and facilitating broader adoption.
Market snapshot - (2026-2033)
Global Market Size
USD 36.64 Billion
Largest Segment
Consumables
Fastest Growth
Software
Growth Rate
22.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global single nucleotide polymorphism (SNP) genotyping market is segmented by product offering type, technology platform, sample specimen matrix, application vector, end user focus and region. Based on product offering type, the market is segmented into consumables, instruments, software and services. Based on technology platform, the market is segmented into polymerase chain reaction, next generation sequencing, microarrays, geneChips, TaqMan allelic discrimination, single nucleotide polymorphism pyrosequencing, SNPlex genotyping systems and Sequenom MassARRAY matrix-assisted laser desorption/ionization time-of-flight. Based on sample specimen matrix, the market is segmented into blood specimen, saliva swabs, buccal cells, plant tissue samples and animal tissue samples. Based on application vector, the market is segmented into diagnostic research, forensics testing, pharmacogenomics analysis, agricultural biotechnology, crop breeding programs and animal livestock optimization. Based on end user focus, the market is segmented into academic research institutes, pharmaceutical corporations, biotechnology establishments, diagnostic laboratories, forensic crime laboratories and agrigenomics centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The next generation sequencing platform is the dominant platform, allowing ultra‐high throughput and comprehensive SNP coverage in a single run, addressing the need for multiplexed discovery and genotyping. Simultaneous sequencing of thousands of loci decreases the time required for assay development and facilitates large population studies. Ongoing improvements in chemistry, read length and cost efficiency increase its attractiveness and reaffirm its pivotal role in research, clinical and agricultural applications.
Meanwhile, TaqMan allelic discrimination platform is emerging as the major high-growth segment as it provides quick, inexpensive single-SNP assays with less complex workflow. Its detection is based on fluorescence and allows real-time genotyping . This is attractive to the users of clinical diagnostics and pharmacogenomics who need a fast turnaround. Assay design ease and compatibility with existing qPCR instrumentation are driving adoption and opening up market opportunities.
The consumables segment is expected to dominate the market as they are the primary reagents that help in the direct execution of SNP assays and are indispensable for routine laboratory workflows. There is a growing demand for reliable high throughput sample preparation and assay kits across multiple platforms, which is driving its widespread use. Its low barrier to entry for labs and ongoing innovation in kit chemistry continue to reinforce its central role, supporting strong demand across research, diagnostics and agriculture.
The software segment is experiencing the highest growth momentum as laboratories are looking for integrated data-analysis solutions that streamline genotype calling and interpretation. Advanced bioinformatics platforms enable real-time visualization, cloud-based collaboration and automated quality control, which reduces turn-around times. The value-added functionality is helping to grow adoption in the areas of precision medicine and research and expanding the market and new sources of income for vendors.
To get detailed segments analysis, Request a Free Sample Report
North America leads the way due to its advanced research ecosystems, significant investment in biotech infrastructure, and well-established regulatory environment that encourages innovation. The region’s strengths include a concentration of top academic institutions, a deep pool of talented scientists, and strong industry and government agency collaborations. Strong funding mechanisms and an aggressive attitude towards intellectual property protection accelerate the commercialization of products, supporting the development of cutting-edge platforms. Furthermore, the increasing popularity of personalized healthcare initiatives in clinical and research settings further boosts the demand, thereby strengthening the market dominance of North America in SNP genotyping technologies.
Single nucleotide polymorphism (SNP) genotyping market outlook in the United States thrives on a vibrant biotech corridor that integrates academic research with entrepreneurial ventures. The ecosystem is characterized by extensive collaborations between pharmaceutical firms and technology providers, fostering rapid translation of assay innovations into clinical practice. Strong venture capital support and a clear pathway for regulatory approval further empower companies to bring high‑throughput solutions to market, sustaining the United States position at the forefront of SNP genotyping advancement.
Single nucleotide polymorphism (SNP) genotyping market forecast in Canada leverages a collaborative network of public research institutes and private enterprises focused on agricultural genomics and health research. Government policies that prioritize genomics research funding create a fertile environment for technology development. The emphasis on translational research bridges laboratory breakthroughs with industry applications, while cross‑border partnerships enhance access to broader markets and expertise, reinforcing Canada’s role as a significant contributor to the global SNP genotyping landscape.
The expansion of Europe is driven by strong public health programs based on genomic insights for disease prevention and personalized therapy. The dense network of research universities and specialized biotech clusters in the region permits knowledge exchange and rapid prototyping of novel genotyping platforms. Harmonised regulations across member states facilitate market entry, and sustained public and private funding streams support long-term development projects. The rising demand from pharmaceutical pipelines for accurate biomarker identification and a growing focus on agricultural genomics, both of which have multi-sectoral draw, heighten Europe’s standing as a vibrant hub for SNP genotyping innovation.
Single nucleotide polymorphism (SNP) genotyping market regional outlook in Germany is anchored by world‑class research institutes and a robust pharmaceutical sector that heavily invests in genomic solutions. Collaborative consortia between universities, biotech firms, and clinical centers accelerate the translation of assay technologies into routine diagnostics. Strong intellectual property protections and supportive governmental programs nurture start‑ups, ensuring a steady pipeline of innovative platforms that sustain Germany’s dominant role in the European market.
Single nucleotide polymorphism (SNP) genotyping market regional forecast in the United Kingdom benefits from an entrepreneurial climate that blends leading academic research with agile biotech enterprises. Strategic initiatives aimed at integrating genomics into the national health service drive adoption of high‑resolution genotyping tools across clinical pathways. A vibrant venture capital scene and a collaborative policy environment encourage rapid scaling of novel technologies, positioning the United Kingdom as a fast‑growing driver of SNP genotyping adoption across Europe.
Single nucleotide polymorphism (SNP) genotyping market analytsis in France is emerging through targeted investments in life‑science research clusters and a growing emphasis on precision medicine within the healthcare system. Partnerships between academic laboratories and biotech innovators foster the development of customized genotyping solutions. Government incentives aimed at accelerating translational research, combined with a rising awareness of genomic applications in agriculture, underpin the expanding footprint of SNP genotyping activities in France.
Asia Pacific is cementing its position with the coupling of large-scale research initiatives with growing biotech manufacturing capabilities. The demand for high-throughput SNP assays is driven by the region’s emphasis on incorporating genomics into public health programs. Policies that promote technology transfer and local production by the government help reduce dependence on imported platforms, and a rising talent pool drives indigenous innovation. Multinational companies and regional research institutes are working together to speed up the development of affordable solutions suited to specific market needs, which will further strengthen the growing role of Asia Pacific in the global SNP genotyping area.
Single nucleotide polymorphism (SNP) genotyping market penetration in Japan is driven by a strong tradition of precision medicine research within academic hospitals and a commitment to integrating genomic data into national health strategies. Close ties between pharmaceutical companies and technology developers foster rapid prototyping of high‑accuracy genotyping platforms. Government‑backed research programs and a focus on quality assurance ensure that Japan remains a key contributor to the advancement of SNP genotyping technologies across the region.
Single nucleotide polymorphism (SNP) genotyping industry in South Korea benefits from a dynamic biotech sector that emphasizes rapid commercialization of genomic tools. Collaborative networks linking universities, contract research organizations, and industry players accelerate the translation of innovative assay designs into marketable products. Public policy that supports scientific entrepreneurship, combined with a growing domestic demand for personalized healthcare solutions, positions South Korea as an emerging leader enhancing the overall strength of the Asia Pacific SNP genotyping market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Expanding Role Of Personalized Therapy
Increasing Adoption Of SNP Arrays
High Cost Of Genotyping Platforms
Regulatory Complexity Across Regions
Request Free Customization of this report to help us to meet your business objectives.
The global SNP genotyping market is characterized by intense competition among established life science companies that continue to invest in high-throughput genotyping platforms, automation, bioinformatics, and artificial intelligence to improve the speed, accuracy, and scalability of genomic analysis. Leading market participants are expanding their product portfolios through strategic collaborations, acquisitions, and investments in next-generation sequencing (NGS), PCR-based genotyping, and cloud-enabled data analysis platforms to address growing demand from precision medicine, agricultural genomics, pharmaceutical research, and population-scale genomics initiatives. Increasing adoption of AI-assisted genomic interpretation and integrated bioinformatics workflows is further accelerating innovation, enabling companies to deliver comprehensive solutions that improve laboratory productivity and support large-scale genomic research.
Top Player’s Company Profile
Recent Developments in the Single Nucleotide Polymorphism (SNP) Genotyping Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis the market is being propelled primarily by the expanding role of personalized therapy, which pushes laboratories to adopt high‑throughput SNP panels, while the growing adoption of SNP arrays serves as a second driver by enabling large‑scale association studies at lower cost and spurring investment in AI‑enhanced automation. The consumables segment dominates because reagents and assay kits are essential for every workflow. North America remains the leading region thanks to its strong research ecosystem, extensive academia‑industry collaborations and robust biotech financing. However, the high cost of genotyping platforms restrains adoption in budget‑constrained settings, slowing penetration in smaller labs and emerging markets.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 36.64 Billion |
| Market size value in 2033 | USD 221.0 Billion |
| Growth Rate | 22.1% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Single Nucleotide Polymorphism (SNP) Genotyping Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Single Nucleotide Polymorphism (SNP) Genotyping Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Single Nucleotide Polymorphism (SNP) Genotyping Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Single Nucleotide Polymorphism (SNP) Genotyping Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Single Nucleotide Polymorphism (Snp) Genotyping Market size was valued at USD 36.64 Billion in 2024 and is poised to grow from USD 44.74 Billion in 2025 to USD 221.0 Billion by 2033, growing at a CAGR of 22.1% during the forecast period (2026-2033).
The SNP genotyping market is shaped by intense competition as leading firms pursue strategic M&A, form cross‑industry partnerships, and accelerate technology innovation to capture emerging clinical and agricultural applications; recent examples include a high‑profile acquisition of a niche assay platform by a major diagnostics group and a joint venture between a genomics company and a cloud‑computing provider to deliver AI‑enhanced variant analysis, underscoring the race to differentiate through integrated solutions. 'Illumina Inc.', 'Thermo Fisher Scientific Inc.', 'QIAGEN N.V.', 'Agilent Technologies Inc.', 'Bio-Rad Laboratories Inc.', 'Standard BioTools Inc.', 'F. Hoffmann-La Roche Ltd', 'LGC Biosearch Technologies', 'Eurofins Scientific SE', 'GenScript Biotech Corporation', 'Takara Bio Inc.', 'New England Biolabs Inc.', 'Promega Corporation', 'Integrated DNA Technologies Inc.', 'PerkinElmer Inc.', 'Macrogen Inc.', 'BGI Group', 'ArrayGen Technologies Pvt. Ltd.', 'Novogene Co. Ltd.', 'Genos'
The shift toward personalized therapy drives SNP genotyping demand because clinicians require detailed genetic variation data to tailor drug selection and dosage. By identifying individual single nucleotide differences, physicians can predict therapeutic response, reduce adverse events, and improve patient outcomes. This clinical relevance encourages healthcare providers to integrate SNP testing into routine diagnostic workflows, prompting laboratories to expand service offerings and prompting technology vendors to enhance assay sensitivity and throughput, thereby fueling market expansion across global healthcare systems in the near future.
Precision Medicine Integration: The convergence of SNP genotyping with precision‑medicine initiatives is accelerating the adoption of targeted therapeutic strategies. Healthcare providers are increasingly leveraging genotype‑driven risk assessments to personalize treatment pathways, fostering deeper collaboration between diagnostics firms and pharmaceutical companies. This synergy expands demand for high‑throughput, clinically validated SNP panels, prompting vendors to develop integrated data platforms that seamlessly connect genetic insights with electronic health records and real‑world evidence, ultimately driving broader market penetration across diverse patient populations and emerging therapeutic areas globally.
Why does North America Dominate the Global Single Nucleotide Polymorphism (SNP) Genotyping Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
